Preparation and in vitro and in vivo evaluation of HupA PLGA microsphere.

Liang Ye,Fenghua Fu,Wanhui Liu,Kaoxiang Sun,Youxin Li,Jie He,Xin Yu,Pengfei Yu,Jingwei Tian

2013-01-01

Pakistan Journal of Pharmaceutical Sciences

Abstract:Acetylcholinesterase inhibitors (AChEIs), including Huperzine A (HupA), have been the mainstay of treatment for Alzheimer's disease (AD). However, AChEIs can cause gastrointestinal side effects, which has been related to the high C-max, and short t(max) after oral administration. Clinical trials have verified that extended-release formulation with lower C-max and prolonged t(max)., such as rivastigmine patch, could perform a similar efficacy with significantly improved tolerability compared with the oral formulations. In this study, we developed an extended-release microspheres formulation of HupA (called as HAM) with poly(lactide-co-glycolide) (PLGA) as drug carrier. HAM has showed the loading rate as 1.35% (w/w) and yielded 42% with mean particle size at 72.6 mu m. In vitro and in vivo pharmacokinetics studies have showed that HAM produced a relatively smooth and continuous drug concentration in 14 days. Furthermore, in vivo pharmacokinetics data have demonstrated that the C-max was lower and the t(max) was considerably later in single intramuscular administration of HAM (1,000 mu g/kg) than the counterparts in single intragastric administration of HAT (75 mu g/kg/d). Meanwhile, HAM has performed a continuous inhibition to brain AChE activity in normal rats and improvement of memory deficit in A beta(1-40) i.c.v. infused AD rat model for 14 days. The results have suggested that HAM has performed good extended-release properties and good prolonged pharmacological efficacy in vivo in the 2-week period, and could exert a similar efficacy with significantly lowered gastrointestinal side effects as compared with oral formulation.